<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35474517</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-1136</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>70</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Glia</Title>
          <ISOAbbreviation>Glia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis-linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice.</ArticleTitle>
        <Pagination>
          <StartPage>1426</StartPage>
          <EndPage>1449</EndPage>
          <MedlinePgn>1426-1449</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/glia.24183</ELocationID>
        <Abstract>
          <AbstractText>Genetic mutations that cause amyotrophic lateral sclerosis (ALS), a progressively lethal motor neuron disease, are commonly found in ubiquitously expressed genes. In addition to direct defects within motor neurons, growing evidence suggests that dysfunction of non-neuronal cells is also an important driver of disease. Previously, we demonstrated that mutations in DNA/RNA binding protein fused in sarcoma (FUS) induce neurotoxic phenotypes in astrocytes in vitro, via activation of the NF-κB pathway and release of pro-inflammatory cytokine TNFα. Here, we developed an intraspinal cord injection model to test whether astrocyte-specific expression of ALS-causative FUS<sup>R521G</sup> variant (mtFUS) causes neuronal damage in vivo. We show that restricted expression of mtFUS in astrocytes is sufficient to induce death of spinal motor neurons leading to motor deficits through upregulation of TNFα. We further demonstrate that TNFα is a key toxic molecule as expression of mtFUS in TNFα knockout animals does not induce pathogenic changes. Accordingly, in mtFUS-transduced animals, administration of TNFα neutralizing antibodies prevents neurodegeneration and motor dysfunction. Together, these studies strengthen evidence that astrocytes contribute to disease in ALS and establish, for the first time, that FUS-ALS astrocytes induce pathogenic changes to motor neurons in vivo. Our work identifies TNFα as the critical driver of mtFUS-astrocytic toxicity and demonstrates therapeutic success of targeting TNFα to attenuate motor neuron dysfunction and death. Ultimately, through defining and subsequently targeting this toxic mechanism, we provide a viable FUS-ALS specific therapeutic strategy, which may also be applicable to sporadic ALS where FUS activity and cellular localization are frequently perturbed.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. GLIA published by Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jensen</LastName>
            <ForeName>Brigid K</ForeName>
            <Initials>BK</Initials>
            <Identifier Source="ORCID">0000-0003-1624-6307</Identifier>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McAvoy</LastName>
            <ForeName>Kevin J</ForeName>
            <Initials>KJ</Initials>
            <Identifier Source="ORCID">0000-0002-0025-1921</Identifier>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heinsinger</LastName>
            <ForeName>Nicolette M</ForeName>
            <Initials>NM</Initials>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lepore</LastName>
            <ForeName>Angelo C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ilieva</LastName>
            <ForeName>Hristelina</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haeusler</LastName>
            <ForeName>Aaron R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trotti</LastName>
            <ForeName>Davide</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-6338-6404</Identifier>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pasinelli</LastName>
            <ForeName>Piera</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R00 NS091486</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS110385</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS079702</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS109150</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21-NS0103118</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 NS116761</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS051488</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1-AG057882</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00 NS091486</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS110385</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS079702</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS109150</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21-NS0103118</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 NS116761</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS051488</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1-AG057882</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Glia</MedlineTA>
        <NlmUniqueID>8806785</NlmUniqueID>
        <ISSNLinking>0894-1491</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012509" MajorTopicYN="Y">Sarcoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword>
        <Keyword MajorTopicYN="N">astrocytes</Keyword>
        <Keyword MajorTopicYN="N">fused in sarcoma</Keyword>
        <Keyword MajorTopicYN="N">motor deficit</Keyword>
        <Keyword MajorTopicYN="N">non-cell autonomous toxicity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35474517</ArticleId>
        <ArticleId IdType="doi">10.1002/glia.24183</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Ajmone-Cat, M. A., Onori, A., Toselli, C., Stronati, E., Morlando, M., Bozzoni, I., Monni, E., Kokaia, Z., Lupo, G., Minghetti, L., Biagioni, S., &amp; Cacci, E. (2019). Increased FUS levels in astrocytes leads to astrocyte and microglia activation and neuronal death. Scientific Reports, 9(1), 4572.</Citation>
        </Reference>
        <Reference>
          <Citation>Averback, P. (1986). A new type of inclusion body in human spinal cord. Acta Neuropathologica, 71(1-2), 106-110.</Citation>
        </Reference>
        <Reference>
          <Citation>Bacskai, T., Fu, Y., Sengul, G., Rusznak, Z., Paxinos, G., &amp; Watson, C. (2013). Musculotopic organization of the motor neurons supplying forelimb and shoulder girdle muscles in the mouse. Brain Structure &amp; Function, 218(1), 221-238.</Citation>
        </Reference>
        <Reference>
          <Citation>Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., Beattie, M. S., &amp; Malenka, R. C. (2002). Control of synaptic strength by glial TNFalpha. Science, 295(5563), 2282-2285.</Citation>
        </Reference>
        <Reference>
          <Citation>Brambilla, L., Guidotti, G., Martorana, F., Iyer, A. M., Aronica, E., Valori, C. F., &amp; Rossi, D. (2016). Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. Human Molecular Genetics, 25(14), 3080-3095.</Citation>
        </Reference>
        <Reference>
          <Citation>Brambilla, R., Ashbaugh, J. J., Magliozzi, R., Dellarole, A., Karmally, S., Szymkowski, D. E., &amp; Bethea, J. R. (2011). Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain, 134(9), 2736-2754.</Citation>
        </Reference>
        <Reference>
          <Citation>Brohawn, D. G., O'Brien, L. C., &amp; Bennett, J. P., Jr. (2016). RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord. PLoS One, 11(8), e0160520.</Citation>
        </Reference>
        <Reference>
          <Citation>Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., &amp; Cleveland, D. W. (1997). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron, 18(2), 327-338.</Citation>
        </Reference>
        <Reference>
          <Citation>Cereda, C., Baiocchi, C., Bongioanni, P., Cova, E., Guareschi, S., Metelli, M. R., Rossi, B., Sbalsi, I., Cuccia, M. C., &amp; Ceroni, M. (2008). TNF and sTNFR1/2 plasma levels in ALS patients. Journal of Neuroimmunology, 194(1-2), 123-131.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, L. (2021). FUS mutation is probably the most common pathogenic gene for JALS, especially sporadic JALS. Revue Neurologique (Paris), 177(4), 333-340.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombo, E., &amp; Farina, C. (2016). Astrocytes: Key regulators of neuroinflammation. Trends in Immunology, 37(9), 608-620.</Citation>
        </Reference>
        <Reference>
          <Citation>Conlon, E. G., Lu, L., Sharma, A., Yamazaki, T., Tang, T., Shneider, N. A., &amp; Manley, J. L. (2016). The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife, 5. https://doi.org/10.7554/elife.17820</Citation>
        </Reference>
        <Reference>
          <Citation>Crosio, C., Valle, C., Casciati, A., Iaccarino, C., &amp; Carri, M. T. (2011). Astroglial inhibition of NF-kappaB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS). PLoS One, 6(3), e17187.</Citation>
        </Reference>
        <Reference>
          <Citation>Deng, H., Gao, K., &amp; Jankovic, J. (2014). The role of FUS gene variants in neurodegenerative diseases. Nature Reviews. Neurology, 10(6), 337-348.</Citation>
        </Reference>
        <Reference>
          <Citation>Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., &amp; Eggan, K. (2007). Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nature Neuroscience, 10(5), 608-614.</Citation>
        </Reference>
        <Reference>
          <Citation>Dokalis, N., &amp; Prinz, M. (2018). Astrocytic NF-κB brings the best and worst out of microglia. The EMBO Journal, 37(16). https://doi.org/10.15252/embj.2018100130</Citation>
        </Reference>
        <Reference>
          <Citation>Dormann, D., &amp; Haass, C. (2011). TDP-43 and FUS: A nuclear affair. Trends in Neurosciences, 34(7), 339-348.</Citation>
        </Reference>
        <Reference>
          <Citation>Dormann, D., Madl, T., Valori, C. F., Bentmann, E., Tahirovic, S., Abou-Ajram, C., Kremmer, E., Ansorge, O., Mackenzie, I. R., Neumann, M., &amp; Haass, C. (2012). Arginine methylation next to the PY-NLS modulates transportin binding and nuclear import of FUS. The EMBO Journal, 31(22), 4258-4275.</Citation>
        </Reference>
        <Reference>
          <Citation>Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M. E., Mackenzie, I. R., Capell, A., Schmid, B., Neumann, M., &amp; Haass, C. (2010). ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. The EMBO Journal, 29(16), 2841-2857.</Citation>
        </Reference>
        <Reference>
          <Citation>Endo, K., Ishigaki, S., Masamizu, Y., Fujioka, Y., Watakabe, A., Yamamori, T., Hatanaka, N., Nambu, A., Okado, H., Katsuno, M., Watanabe, H., Matsuzaki, M., &amp; Sobue, G. (2018). Silencing of FUS in the common marmoset (Callithrix jacchus) brain via stereotaxic injection of an adeno-associated virus encoding shRNA. Neuroscience Research, 130, 56-64.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferrer, I., Legati, A., Garcia-Monco, J. C., Gomez-Beldarrain, M., Carmona, M., Blanco, R., Seeley, W. W., &amp; Coppola, G. (2015). Familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy. Journal of Neuropathology and Experimental Neurology, 74(4), 370-379.</Citation>
        </Reference>
        <Reference>
          <Citation>Filipi, T., Hermanova, Z., Tureckova, J., Vanatko, O., &amp; Anderova, M. (2020). Glial cells-the strategic targets in amyotrophic lateral sclerosis treatment. Journal of Clinical Medicine, 9(1), 261. https://doi.org/10.3390/jcm9010261</Citation>
        </Reference>
        <Reference>
          <Citation>Finsterbusch, M., Hall, P., Li, A., Devi, S., Westhorpe, C. L., Kitching, A. R., &amp; Hickey, M. J. (2016). Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus. Proceedings of the National Academy of Sciences of the United States of America, 113(35), 5172-5181.</Citation>
        </Reference>
        <Reference>
          <Citation>Frakes, A. E., Ferraiuolo, L., Haidet-Phillips, A. M., Schmelzer, L., Braun, L., Miranda, C. J., Ladner, K. J., Bevan, A. K., Foust, K. D., Godbout, J. P., Popovich, P. G., Guttridge, D. C., &amp; Kaspar, B. K. (2014). Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron, 81(5), 1009-1023.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujimori, K., Ishikawa, M., Otomo, A., Atsuta, N., Nakamura, R., Akiyama, T., Hadano, S., Aoki, M., Saya, H., Sobue, G., &amp; Okano, H. (2018). Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nature Medicine, 24(10), 1579-1589.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujioka, Y., Ishigaki, S., Masuda, A., Iguchi, Y., Udagawa, T., Watanabe, H., Katsuno, M., Ohno, K., &amp; Sobue, G. (2013). FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD. Scientific Reports, 3, 2388.</Citation>
        </Reference>
        <Reference>
          <Citation>Gandelman, M., Peluffo, H., Beckman, J. S., Cassina, P., &amp; Barbeito, L. (2010). Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: Implications for amyotrophic lateral sclerosis. Journal of Neuroinflammation, 7, 33.</Citation>
        </Reference>
        <Reference>
          <Citation>Gane, J. M., Stockley, R. A., &amp; Sapey, E. (2016). TNF-alpha autocrine feedback loops in human monocytes: The pro- and anti-inflammatory roles of the TNF-alpha receptors support the concept of selective TNFR1 blockade in vivo. Journal of Immunology Research, 2016, 1079851.</Citation>
        </Reference>
        <Reference>
          <Citation>Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W. D., &amp; Elliott, J. L. (2000). Restricted expression of G86R cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. The Journal of Neuroscience, 20(2), 660-665.</Citation>
        </Reference>
        <Reference>
          <Citation>Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., Neville, H. E., Boylan, K., Mozaffar, T., Belsh, J. M., Ravits, J., Bedlack, R. S., Graves, M. C., McCluskey, L. F., Barohn, R. J., &amp; Western, A. L. S. S. G. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurology, 6(12), 1045-1053.</Citation>
        </Reference>
        <Reference>
          <Citation>Gowing, G., Dequen, F., Soucy, G., &amp; Julien, J. P. (2006). Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. The Journal of Neuroscience, 26(44), 11397-11402.</Citation>
        </Reference>
        <Reference>
          <Citation>Guidotti, G., Scarlata, C., Brambilla, L., &amp; Rossi, D. (2021). Tumor necrosis factor alpha in amyotrophic lateral sclerosis: Friend or foe? Cells, 10(3), 518-537. https://doi.org/10.3390/cells10030518</Citation>
        </Reference>
        <Reference>
          <Citation>Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., Klaus, F. R., Kollias, G., Fontana, A., Pryce, C. R., Suter, T., &amp; Volterra, A. (2015). Neuroinflammatory TNFalpha impairs memory via astrocyte signaling. Cell, 163(7), 1730-1741.</Citation>
        </Reference>
        <Reference>
          <Citation>Hensley, K., Fedynyshyn, J., Ferrell, S., Floyd, R. A., Gordon, B., Grammas, P., Hamdheydari, L., Mhatre, M., Mou, S., Pye, Q. N., Stewart, C., West, M., West, S., &amp; Williamson, K. S. (2003). Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiology of Disease, 14(1), 74-80.</Citation>
        </Reference>
        <Reference>
          <Citation>Hewitt, C., Kirby, J., Highley, J. R., Hartley, J. A., Hibberd, R., Hollinger, H. C., Williams, T. L., Ince, P. G., McDermott, C. J., &amp; Shaw, P. J. (2010). Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Archives of Neurology, 67(4), 455-461.</Citation>
        </Reference>
        <Reference>
          <Citation>Hicks, G. G., Singh, N., Nashabi, A., Mai, S., Bozek, G., Klewes, L., Arapovic, D., White, E. K., Koury, M. J., Oltz, E. M., Van Kaer, L., &amp; Ruley, H. E. (2000). Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nature Genetics, 24(2), 175-179.</Citation>
        </Reference>
        <Reference>
          <Citation>Ikenaka, K., Ishigaki, S., Iguchi, Y., Kawai, K., Fujioka, Y., Yokoi, S., Abdelhamid, R. F., Nagano, S., Mochizuki, H., Katsuno, M., &amp; Sobue, G. (2020). Characteristic features of FUS inclusions in spinal motor neurons of sporadic amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 79(4), 370-377.</Citation>
        </Reference>
        <Reference>
          <Citation>Kalliolias, G. D., &amp; Ivashkiv, L. B. (2016). TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nature Reviews Rheumatology, 12(1), 49-62.</Citation>
        </Reference>
        <Reference>
          <Citation>Kamo, H., Haebara, H., Akiguchi, I., Kameyama, M., Kimura, H., &amp; McGeer, P. L. (1987). A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathologica, 74(1), 33-38.</Citation>
        </Reference>
        <Reference>
          <Citation>Kemanetzoglou, E., &amp; Andreadou, E. (2017). CNS demyelination with TNF-alpha blockers. Current Neurology and Neuroscience Reports, 17(4), 36.</Citation>
        </Reference>
        <Reference>
          <Citation>Kia, A., McAvoy, K., Krishnamurthy, K., Trotti, D., &amp; Pasinelli, P. (2018). Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. GLIA, 66(5), 1016-1033.</Citation>
        </Reference>
        <Reference>
          <Citation>Kiaei, M., Petri, S., Kipiani, K., Gardian, G., Choi, D. K., Chen, J., Calingasan, N. Y., Schafer, P., Muller, G. W., Stewart, C., Hensley, K., &amp; Beal, M. F. (2006). Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience, 26(9), 2467-2473.</Citation>
        </Reference>
        <Reference>
          <Citation>Kimura, T., &amp; Budka, H. (1984). Glial bundles in spinal nerve roots. An immunocytochemical study stressing their nonspecificity in various spinal cord and peripheral nerve diseases. Acta Neuropathologica, 65(1), 46-52.</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayashi, Z., Tsuchiya, K., Arai, T., Aoki, M., Hasegawa, M., Ishizu, H., Akiyama, H., &amp; Mizusawa, H. (2010). Occurrence of basophilic inclusions and FUS-immunoreactive neuronal and glial inclusions in a case of familial amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 293(1-2), 6-11.</Citation>
        </Reference>
        <Reference>
          <Citation>Kushner, P. D., Stephenson, D. T., &amp; Wright, S. (1991). Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. Journal of Neuropathology and Experimental Neurology, 50(3), 263-277.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwiatkowski, T. J., Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., Valdmanis, P., Rouleau, G. A., Hosler, B. A., Cortelli, P., de Jong, P. J., Yoshinaga, Y., Haines, J. L., Pericak-Vance, M. A., Yan, J., &amp; Brown, R. H., Jr. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323(5918), 1205-1208.</Citation>
        </Reference>
        <Reference>
          <Citation>Li, K., Hala, T. J., Seetharam, S., Poulsen, D. J., Wright, M. C., &amp; Lepore, A. C. (2015). GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease. Neurobiology of Disease, 78, 12-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Li, K., Nicaise, C., Sannie, D., Hala, T. J., Javed, E., Parker, J. L., Putatunda, R., Regan, K. A., Suain, V., Brion, J. P., Rhoderick, F., Wright, M. C., Poulsen, D. J., &amp; Lepore, A. C. (2014). Overexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury. The Journal of Neuroscience, 34(22), 7622-7638.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu, C. H., Allen, K., Oei, F., Leoni, E., Kuhle, J., Tree, T., Fratta, P., Sharma, N., Sidle, K., Howard, R., Orrell, R., Fish, M., Greensmith, L., Pearce, N., Gallo, V., &amp; Malaspina, A. (2016). Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurology Neuroimmunology &amp; Neuroinflammation, 3(4), e244.</Citation>
        </Reference>
        <Reference>
          <Citation>Machamer, J. B., Collins, S. E., &amp; Lloyd, T. E. (2014). The ALS gene FUS regulates synaptic transmission at the drosophila neuromuscular junction. Human Molecular Genetics, 23(14), 3810-3822.</Citation>
        </Reference>
        <Reference>
          <Citation>McCauley, M. E., &amp; Baloh, R. H. (2019). Inflammation in ALS/FTD pathogenesis. Acta Neuropathologica, 137(5), 715-730.</Citation>
        </Reference>
        <Reference>
          <Citation>McCoy, M. K., &amp; Tansey, M. G. (2008). TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. Journal of Neuroinflammation, 5, 45.</Citation>
        </Reference>
        <Reference>
          <Citation>Meyer, K., Ferraiuolo, L., Miranda, C. J., Likhite, S., McElroy, S., Renusch, S., Ditsworth, D., Lagier-Tourenne, C., Smith, R. A., Ravits, J., Burghes, A. H., Shaw, P. J., Cleveland, D. W., Kolb, S. J., &amp; Kaspar, B. K. (2014). Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proceedings of the National Academy of Sciences of the United States of America, 111(2), 829-832.</Citation>
        </Reference>
        <Reference>
          <Citation>Migheli, A., Piva, R., Atzori, C., Troost, D., &amp; Schiffer, D. (1997). C-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 56(12), 1314-1322.</Citation>
        </Reference>
        <Reference>
          <Citation>Mizielinska, S., Lashley, T., Norona, F. E., Clayton, E. L., Ridler, C. E., Fratta, P., &amp; Isaacs, A. M. (2013). C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathologica, 126(6), 845-857.</Citation>
        </Reference>
        <Reference>
          <Citation>Mulder, D. W. (1982). Clinical limits of amyotrophic lateral sclerosis. Advances in Neurology, 36, 15-22.</Citation>
        </Reference>
        <Reference>
          <Citation>Murayama, S., Inoue, K., Kawakami, H., Bouldin, T. W., &amp; Suzuki, K. (1991). A unique pattern of astrocytosis in the primary motor area in amyotrophic lateral sclerosis. Acta Neuropathologica, 82(6), 456-461.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., &amp; Przedborski, S. (2007). Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature Neuroscience, 10(5), 615-622.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagy, D., Kato, T., &amp; Kushner, P. D. (1994). Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. Journal of Neuroscience Research, 38(3), 336-347.</Citation>
        </Reference>
        <Reference>
          <Citation>Novrup, H. G., Bracchi-Ricard, V., Ellman, D. G., Ricard, J., Jain, A., Runko, E., Lyck, L., Yli-Karjanmaa, M., Szymkowski, D. E., Pearse, D. D., Lambertsen, K. L., &amp; Bethea, J. R. (2014). Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroinflammation, 11, 159.</Citation>
        </Reference>
        <Reference>
          <Citation>Pasparakis, M., Alexopoulou, L., Episkopou, V., &amp; Kollias, G. (1996). Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. The Journal of Experimental Medicine, 184(4), 1397-1411.</Citation>
        </Reference>
        <Reference>
          <Citation>Pekalski, J., Zuk, P. J., Kochanczyk, M., Junkin, M., Kellogg, R., Tay, S., &amp; Lipniacki, T. (2013). Spontaneous NF-kappaB activation by autocrine TNFalpha signaling: A computational analysis. PLoS One, 8(11), e78887.</Citation>
        </Reference>
        <Reference>
          <Citation>Phatnani, H. P., Guarnieri, P., Friedman, B. A., Carrasco, M. A., Muratet, M., O'Keeffe, S., Nwakeze, C., Pauli-Behn, F., Newberry, K. M., Meadows, S. K., Tapia, J. C., Myers, R. M., &amp; Maniatis, T. (2013). Intricate interplay between astrocytes and motor neurons in ALS. Proceedings of the National Academy of Sciences of the United States of America, 110(8), 756-765.</Citation>
        </Reference>
        <Reference>
          <Citation>Poloni, M., Facchetti, D., Mai, R., Micheli, A., Agnoletti, L., Francolini, G., Mora, G., Camana, C., Mazzini, L., &amp; Bachetti, T. (2000). Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neuroscience Letters, 287(3), 211-214.</Citation>
        </Reference>
        <Reference>
          <Citation>Popova, L. M., &amp; Sakharova, A. V. (1982). Virus-like inclusions in the cells of the central nervous system in amyotrophic lateral sclerosis. Arkhiv Patologii, 44(10), 28-33.</Citation>
        </Reference>
        <Reference>
          <Citation>Qian, K., Huang, H., Peterson, A., Hu, B., Maragakis, N. J., Ming, G. L., Chen, H., &amp; Zhang, S. C. (2017). Sporadic ALS astrocytes induce neuronal degeneration in vivo. Stem Cell Reports, 8(4), 843-855.</Citation>
        </Reference>
        <Reference>
          <Citation>Qosa, H., Lichter, J., Sarlo, M., Markandaiah, S. S., McAvoy, K., Richard, J. P., Jablonski, M. R., Maragakis, N. J., Pasinelli, P., &amp; Trotti, D. (2016). Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. GLIA, 64(8), 1298-1313.</Citation>
        </Reference>
        <Reference>
          <Citation>Rademakers, R., Stewart, H., Dejesus-Hernandez, M., Krieger, C., Graff-Radford, N., Fabros, M., Briemberg, H., Cashman, N., Eisen, A., &amp; Mackenzie, I. R. (2010). Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle &amp; Nerve, 42(2), 170-176.</Citation>
        </Reference>
        <Reference>
          <Citation>Renton, A. E., Chio, A., &amp; Traynor, B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 17(1), 17-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Rostalski, H., Leskela, S., Huber, N., Katisko, K., Cajanus, A., Solje, E., Marttinen, M., Natunen, T., Remes, A. M., Hiltunen, M., &amp; Haapasalo, A. (2019). Astrocytes and microglia as potential contributors to the pathogenesis of C9orf72 repeat expansion-associated FTLD and ALS. Frontiers in Neuroscience, 13, 486.</Citation>
        </Reference>
        <Reference>
          <Citation>Santello, M., Bezzi, P., &amp; Volterra, A. (2011). TNFalpha controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron, 69(5), 988-1001.</Citation>
        </Reference>
        <Reference>
          <Citation>Scekic-Zahirovic, J., Oussini, H. E., Mersmann, S., Drenner, K., Wagner, M., Sun, Y., Allmeroth, K., Dieterle, S., Sinniger, J., Dirrig-Grosch, S., Rene, F., Dormann, D., Haass, C., Ludolph, A. C., Lagier-Tourenne, C., Storkebaum, E., &amp; Dupuis, L. (2017). Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathologica, 133(6), 887-906.</Citation>
        </Reference>
        <Reference>
          <Citation>Sedger, L. M., &amp; McDermott, M. F. (2014). TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine &amp; Growth Factor Reviews, 25(4), 453-472.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma, A., Lyashchenko, A. K., Lu, L., Nasrabady, S. E., Elmaleh, M., Mendelsohn, M., Nemes, A., Tapia, J. C., Mentis, G. Z., &amp; Shneider, N. A. (2016). ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nature Communications, 7, 10465.</Citation>
        </Reference>
        <Reference>
          <Citation>Stellwagen, D., Beattie, E. C., Seo, J. Y., &amp; Malenka, R. C. (2005). Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. The Journal of Neuroscience, 25(12), 3219-3228.</Citation>
        </Reference>
        <Reference>
          <Citation>Stellwagen, D., &amp; Malenka, R. C. (2006). Synaptic scaling mediated by glial TNF-alpha. Nature, 440(7087), 1054-1059.</Citation>
        </Reference>
        <Reference>
          <Citation>Stommel, E. W., Cohen, J. A., Fadul, C. E., Cogbill, C. H., Graber, D. J., Kingman, L., Mackenzie, T., Channon Smith, J. Y., &amp; Harris, B. T. (2009). Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial. Amyotrophic Lateral Sclerosis, 10(5-6), 393-404.</Citation>
        </Reference>
        <Reference>
          <Citation>Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., McLaughlin, P., Snowden, J., Mioshi, E., Roberts-South, A., Benatar, M., HortobaGyi, T., Rosenfeld, J., Silani, V., Ince, P. G., &amp; Turner, M. R. (2017). Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18(3-4), 153-174.</Citation>
        </Reference>
        <Reference>
          <Citation>Suzuki, N., Kato, S., Kato, M., Warita, H., Mizuno, H., Kato, M., Shimakura, N., Akiyama, H., Kobayashi, Z., Konno, H., &amp; Aoki, M. (2012). FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation. Journal of Neuropathology and Experimental Neurology, 71(9), 779-788.</Citation>
        </Reference>
        <Reference>
          <Citation>Swarup, V., Phaneuf, D., Dupre, N., Petri, S., Strong, M., Kriz, J., &amp; Julien, J. P. (2011). Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. The Journal of Experimental Medicine, 208(12), 2429-2447.</Citation>
        </Reference>
        <Reference>
          <Citation>Tateishi, T., Yamasaki, R., Tanaka, M., Matsushita, T., Kikuchi, H., Isobe, N., Ohyagi, Y., &amp; Kira, J. (2010). CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. Journal of Neuroimmunology, 222(1-2), 76-81.</Citation>
        </Reference>
        <Reference>
          <Citation>Tolosa, L., Caraballo-Miralles, V., Olmos, G., &amp; Llado, J. (2011). TNF-alpha potentiates glutamate-induced spinal cord motoneuron death via NF-kappaB. Molecular and Cellular Neurosciences, 46(1), 176-186.</Citation>
        </Reference>
        <Reference>
          <Citation>Tong, J., Huang, C., Bi, F., Wu, Q., Huang, B., Liu, X., Li, F., Zhou, H., &amp; Xia, X. G. (2013). Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. The EMBO Journal, 32(13), 1917-1926.</Citation>
        </Reference>
        <Reference>
          <Citation>Tortarolo, M., Lo Coco, D., Veglianese, P., Vallarola, A., Giordana, M. T., Marcon, G., Beghi, E., Poloni, M., Strong, M. J., Iyer, A. M., Aronica, E., &amp; Bendotti, C. (2017). Amyotrophic lateral sclerosis, a multisystem pathology: Insights into the role of TNFalpha. Mediators of Inflammation, 2017, 2985051.</Citation>
        </Reference>
        <Reference>
          <Citation>Tripathi, P., Rodriguez-Muela, N., Klim, J. R., de Boer, A. S., Agrawal, S., Sandoe, J., Lopes, C. S., Ogliari, K. S., Williams, L. A., Shear, M., Rubin, L. L., Eggan, K., &amp; Zhou, Q. (2017). Reactive astrocytes promote ALS-like degeneration and intracellular protein aggregation in human motor neurons by disrupting autophagy through TGF-beta1. Stem Cell Reports, 9(2), 667-680.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyzack, G. E., Hall, C. E., Sibley, C. R., Cymes, T., Forostyak, S., Carlino, G., Meyer, I. F., Schiavo, G., Zhang, S. C., Gibbons, G. M., Newcombe, J., Patani, R., &amp; Lakatos, A. (2017). A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nature Communications, 8(1), 1164.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyzack, G. E., Luisier, R., Taha, D. M., Neeves, J., Modic, M., Mitchell, J. S., Meyer, I., Greensmith, L., Newcombe, J., Ule, J., Luscombe, N. M., &amp; Patani, R. (2019). Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain, 142(9), 2572-2580.</Citation>
        </Reference>
        <Reference>
          <Citation>Valori, C. F., Brambilla, L., Martorana, F., &amp; Rossi, D. (2014). The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cellular and Molecular Life Sciences, 71(2), 287-297.</Citation>
        </Reference>
        <Reference>
          <Citation>Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K. L., Tripathi, V., Al-Saraj, S., Al-Chalabi, A., Leigh, P. N., Blair, I. P., Nicholson, G., de Belleroche, J., &amp; Shaw, C. E. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323(5918), 1208-1211.</Citation>
        </Reference>
        <Reference>
          <Citation>Vance, C., Scotter, E. L., Nishimura, A. L., Troakes, C., Mitchell, J. C., Kathe, C., Urwin, H., Manser, C., Miller, C. C., Hortobagyi, T., Dragunow, M., Rogelj, B., &amp; Shaw, C. E. (2013). ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Human Molecular Genetics, 22(13), 2676-2688.</Citation>
        </Reference>
        <Reference>
          <Citation>Via, C. S., Shustov, A., Rus, V., Lang, T., Nguyen, P., &amp; Finkelman, F. D. (2001). In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. Journal of Immunology, 167(12), 6821-6826.</Citation>
        </Reference>
        <Reference>
          <Citation>Vucic, S., Rothstein, J. D., &amp; Kiernan, M. C. (2014). Advances in treating amyotrophic lateral sclerosis: Insights from pathophysiological studies. Trends in Neurosciences, 37(8), 433-442.</Citation>
        </Reference>
        <Reference>
          <Citation>Wachter, N., Storch, A., &amp; Hermann, A. (2015). Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16(7-8), 431-441.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, R., Yang, B., &amp; Zhang, D. (2011). Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. GLIA, 59(6), 946-958.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou, Z. Y., Liu, M. S., Li, X. G., &amp; Cui, L. Y. (2016). Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(3-4), 249-252.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou, Z. Y., Zhou, Z. R., Che, C. H., Liu, C. Y., He, R. L., &amp; Huang, H. P. (2017). Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery, and Psychiatry, 88(7), 540-549.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35474517</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-1136</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>70</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Glia</Title>
          <ISOAbbreviation>Glia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis-linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice.</ArticleTitle>
        <Pagination>
          <StartPage>1426</StartPage>
          <EndPage>1449</EndPage>
          <MedlinePgn>1426-1449</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/glia.24183</ELocationID>
        <Abstract>
          <AbstractText>Genetic mutations that cause amyotrophic lateral sclerosis (ALS), a progressively lethal motor neuron disease, are commonly found in ubiquitously expressed genes. In addition to direct defects within motor neurons, growing evidence suggests that dysfunction of non-neuronal cells is also an important driver of disease. Previously, we demonstrated that mutations in DNA/RNA binding protein fused in sarcoma (FUS) induce neurotoxic phenotypes in astrocytes in vitro, via activation of the NF-κB pathway and release of pro-inflammatory cytokine TNFα. Here, we developed an intraspinal cord injection model to test whether astrocyte-specific expression of ALS-causative FUS<sup>R521G</sup> variant (mtFUS) causes neuronal damage in vivo. We show that restricted expression of mtFUS in astrocytes is sufficient to induce death of spinal motor neurons leading to motor deficits through upregulation of TNFα. We further demonstrate that TNFα is a key toxic molecule as expression of mtFUS in TNFα knockout animals does not induce pathogenic changes. Accordingly, in mtFUS-transduced animals, administration of TNFα neutralizing antibodies prevents neurodegeneration and motor dysfunction. Together, these studies strengthen evidence that astrocytes contribute to disease in ALS and establish, for the first time, that FUS-ALS astrocytes induce pathogenic changes to motor neurons in vivo. Our work identifies TNFα as the critical driver of mtFUS-astrocytic toxicity and demonstrates therapeutic success of targeting TNFα to attenuate motor neuron dysfunction and death. Ultimately, through defining and subsequently targeting this toxic mechanism, we provide a viable FUS-ALS specific therapeutic strategy, which may also be applicable to sporadic ALS where FUS activity and cellular localization are frequently perturbed.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. GLIA published by Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jensen</LastName>
            <ForeName>Brigid K</ForeName>
            <Initials>BK</Initials>
            <Identifier Source="ORCID">0000-0003-1624-6307</Identifier>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McAvoy</LastName>
            <ForeName>Kevin J</ForeName>
            <Initials>KJ</Initials>
            <Identifier Source="ORCID">0000-0002-0025-1921</Identifier>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heinsinger</LastName>
            <ForeName>Nicolette M</ForeName>
            <Initials>NM</Initials>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lepore</LastName>
            <ForeName>Angelo C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ilieva</LastName>
            <ForeName>Hristelina</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haeusler</LastName>
            <ForeName>Aaron R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trotti</LastName>
            <ForeName>Davide</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-6338-6404</Identifier>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pasinelli</LastName>
            <ForeName>Piera</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R00 NS091486</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS110385</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS079702</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS109150</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21-NS0103118</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 NS116761</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS051488</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1-AG057882</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00 NS091486</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS110385</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS079702</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS109150</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21-NS0103118</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 NS116761</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS051488</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1-AG057882</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Glia</MedlineTA>
        <NlmUniqueID>8806785</NlmUniqueID>
        <ISSNLinking>0894-1491</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012509" MajorTopicYN="Y">Sarcoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword>
        <Keyword MajorTopicYN="N">astrocytes</Keyword>
        <Keyword MajorTopicYN="N">fused in sarcoma</Keyword>
        <Keyword MajorTopicYN="N">motor deficit</Keyword>
        <Keyword MajorTopicYN="N">non-cell autonomous toxicity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35474517</ArticleId>
        <ArticleId IdType="doi">10.1002/glia.24183</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Ajmone-Cat, M. A., Onori, A., Toselli, C., Stronati, E., Morlando, M., Bozzoni, I., Monni, E., Kokaia, Z., Lupo, G., Minghetti, L., Biagioni, S., &amp; Cacci, E. (2019). Increased FUS levels in astrocytes leads to astrocyte and microglia activation and neuronal death. Scientific Reports, 9(1), 4572.</Citation>
        </Reference>
        <Reference>
          <Citation>Averback, P. (1986). A new type of inclusion body in human spinal cord. Acta Neuropathologica, 71(1-2), 106-110.</Citation>
        </Reference>
        <Reference>
          <Citation>Bacskai, T., Fu, Y., Sengul, G., Rusznak, Z., Paxinos, G., &amp; Watson, C. (2013). Musculotopic organization of the motor neurons supplying forelimb and shoulder girdle muscles in the mouse. Brain Structure &amp; Function, 218(1), 221-238.</Citation>
        </Reference>
        <Reference>
          <Citation>Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., Beattie, M. S., &amp; Malenka, R. C. (2002). Control of synaptic strength by glial TNFalpha. Science, 295(5563), 2282-2285.</Citation>
        </Reference>
        <Reference>
          <Citation>Brambilla, L., Guidotti, G., Martorana, F., Iyer, A. M., Aronica, E., Valori, C. F., &amp; Rossi, D. (2016). Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. Human Molecular Genetics, 25(14), 3080-3095.</Citation>
        </Reference>
        <Reference>
          <Citation>Brambilla, R., Ashbaugh, J. J., Magliozzi, R., Dellarole, A., Karmally, S., Szymkowski, D. E., &amp; Bethea, J. R. (2011). Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain, 134(9), 2736-2754.</Citation>
        </Reference>
        <Reference>
          <Citation>Brohawn, D. G., O'Brien, L. C., &amp; Bennett, J. P., Jr. (2016). RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord. PLoS One, 11(8), e0160520.</Citation>
        </Reference>
        <Reference>
          <Citation>Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., &amp; Cleveland, D. W. (1997). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron, 18(2), 327-338.</Citation>
        </Reference>
        <Reference>
          <Citation>Cereda, C., Baiocchi, C., Bongioanni, P., Cova, E., Guareschi, S., Metelli, M. R., Rossi, B., Sbalsi, I., Cuccia, M. C., &amp; Ceroni, M. (2008). TNF and sTNFR1/2 plasma levels in ALS patients. Journal of Neuroimmunology, 194(1-2), 123-131.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, L. (2021). FUS mutation is probably the most common pathogenic gene for JALS, especially sporadic JALS. Revue Neurologique (Paris), 177(4), 333-340.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombo, E., &amp; Farina, C. (2016). Astrocytes: Key regulators of neuroinflammation. Trends in Immunology, 37(9), 608-620.</Citation>
        </Reference>
        <Reference>
          <Citation>Conlon, E. G., Lu, L., Sharma, A., Yamazaki, T., Tang, T., Shneider, N. A., &amp; Manley, J. L. (2016). The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife, 5. https://doi.org/10.7554/elife.17820</Citation>
        </Reference>
        <Reference>
          <Citation>Crosio, C., Valle, C., Casciati, A., Iaccarino, C., &amp; Carri, M. T. (2011). Astroglial inhibition of NF-kappaB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS). PLoS One, 6(3), e17187.</Citation>
        </Reference>
        <Reference>
          <Citation>Deng, H., Gao, K., &amp; Jankovic, J. (2014). The role of FUS gene variants in neurodegenerative diseases. Nature Reviews. Neurology, 10(6), 337-348.</Citation>
        </Reference>
        <Reference>
          <Citation>Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., &amp; Eggan, K. (2007). Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nature Neuroscience, 10(5), 608-614.</Citation>
        </Reference>
        <Reference>
          <Citation>Dokalis, N., &amp; Prinz, M. (2018). Astrocytic NF-κB brings the best and worst out of microglia. The EMBO Journal, 37(16). https://doi.org/10.15252/embj.2018100130</Citation>
        </Reference>
        <Reference>
          <Citation>Dormann, D., &amp; Haass, C. (2011). TDP-43 and FUS: A nuclear affair. Trends in Neurosciences, 34(7), 339-348.</Citation>
        </Reference>
        <Reference>
          <Citation>Dormann, D., Madl, T., Valori, C. F., Bentmann, E., Tahirovic, S., Abou-Ajram, C., Kremmer, E., Ansorge, O., Mackenzie, I. R., Neumann, M., &amp; Haass, C. (2012). Arginine methylation next to the PY-NLS modulates transportin binding and nuclear import of FUS. The EMBO Journal, 31(22), 4258-4275.</Citation>
        </Reference>
        <Reference>
          <Citation>Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M. E., Mackenzie, I. R., Capell, A., Schmid, B., Neumann, M., &amp; Haass, C. (2010). ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. The EMBO Journal, 29(16), 2841-2857.</Citation>
        </Reference>
        <Reference>
          <Citation>Endo, K., Ishigaki, S., Masamizu, Y., Fujioka, Y., Watakabe, A., Yamamori, T., Hatanaka, N., Nambu, A., Okado, H., Katsuno, M., Watanabe, H., Matsuzaki, M., &amp; Sobue, G. (2018). Silencing of FUS in the common marmoset (Callithrix jacchus) brain via stereotaxic injection of an adeno-associated virus encoding shRNA. Neuroscience Research, 130, 56-64.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferrer, I., Legati, A., Garcia-Monco, J. C., Gomez-Beldarrain, M., Carmona, M., Blanco, R., Seeley, W. W., &amp; Coppola, G. (2015). Familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy. Journal of Neuropathology and Experimental Neurology, 74(4), 370-379.</Citation>
        </Reference>
        <Reference>
          <Citation>Filipi, T., Hermanova, Z., Tureckova, J., Vanatko, O., &amp; Anderova, M. (2020). Glial cells-the strategic targets in amyotrophic lateral sclerosis treatment. Journal of Clinical Medicine, 9(1), 261. https://doi.org/10.3390/jcm9010261</Citation>
        </Reference>
        <Reference>
          <Citation>Finsterbusch, M., Hall, P., Li, A., Devi, S., Westhorpe, C. L., Kitching, A. R., &amp; Hickey, M. J. (2016). Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus. Proceedings of the National Academy of Sciences of the United States of America, 113(35), 5172-5181.</Citation>
        </Reference>
        <Reference>
          <Citation>Frakes, A. E., Ferraiuolo, L., Haidet-Phillips, A. M., Schmelzer, L., Braun, L., Miranda, C. J., Ladner, K. J., Bevan, A. K., Foust, K. D., Godbout, J. P., Popovich, P. G., Guttridge, D. C., &amp; Kaspar, B. K. (2014). Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron, 81(5), 1009-1023.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujimori, K., Ishikawa, M., Otomo, A., Atsuta, N., Nakamura, R., Akiyama, T., Hadano, S., Aoki, M., Saya, H., Sobue, G., &amp; Okano, H. (2018). Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nature Medicine, 24(10), 1579-1589.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujioka, Y., Ishigaki, S., Masuda, A., Iguchi, Y., Udagawa, T., Watanabe, H., Katsuno, M., Ohno, K., &amp; Sobue, G. (2013). FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD. Scientific Reports, 3, 2388.</Citation>
        </Reference>
        <Reference>
          <Citation>Gandelman, M., Peluffo, H., Beckman, J. S., Cassina, P., &amp; Barbeito, L. (2010). Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: Implications for amyotrophic lateral sclerosis. Journal of Neuroinflammation, 7, 33.</Citation>
        </Reference>
        <Reference>
          <Citation>Gane, J. M., Stockley, R. A., &amp; Sapey, E. (2016). TNF-alpha autocrine feedback loops in human monocytes: The pro- and anti-inflammatory roles of the TNF-alpha receptors support the concept of selective TNFR1 blockade in vivo. Journal of Immunology Research, 2016, 1079851.</Citation>
        </Reference>
        <Reference>
          <Citation>Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W. D., &amp; Elliott, J. L. (2000). Restricted expression of G86R cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. The Journal of Neuroscience, 20(2), 660-665.</Citation>
        </Reference>
        <Reference>
          <Citation>Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., Neville, H. E., Boylan, K., Mozaffar, T., Belsh, J. M., Ravits, J., Bedlack, R. S., Graves, M. C., McCluskey, L. F., Barohn, R. J., &amp; Western, A. L. S. S. G. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurology, 6(12), 1045-1053.</Citation>
        </Reference>
        <Reference>
          <Citation>Gowing, G., Dequen, F., Soucy, G., &amp; Julien, J. P. (2006). Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. The Journal of Neuroscience, 26(44), 11397-11402.</Citation>
        </Reference>
        <Reference>
          <Citation>Guidotti, G., Scarlata, C., Brambilla, L., &amp; Rossi, D. (2021). Tumor necrosis factor alpha in amyotrophic lateral sclerosis: Friend or foe? Cells, 10(3), 518-537. https://doi.org/10.3390/cells10030518</Citation>
        </Reference>
        <Reference>
          <Citation>Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., Klaus, F. R., Kollias, G., Fontana, A., Pryce, C. R., Suter, T., &amp; Volterra, A. (2015). Neuroinflammatory TNFalpha impairs memory via astrocyte signaling. Cell, 163(7), 1730-1741.</Citation>
        </Reference>
        <Reference>
          <Citation>Hensley, K., Fedynyshyn, J., Ferrell, S., Floyd, R. A., Gordon, B., Grammas, P., Hamdheydari, L., Mhatre, M., Mou, S., Pye, Q. N., Stewart, C., West, M., West, S., &amp; Williamson, K. S. (2003). Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiology of Disease, 14(1), 74-80.</Citation>
        </Reference>
        <Reference>
          <Citation>Hewitt, C., Kirby, J., Highley, J. R., Hartley, J. A., Hibberd, R., Hollinger, H. C., Williams, T. L., Ince, P. G., McDermott, C. J., &amp; Shaw, P. J. (2010). Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Archives of Neurology, 67(4), 455-461.</Citation>
        </Reference>
        <Reference>
          <Citation>Hicks, G. G., Singh, N., Nashabi, A., Mai, S., Bozek, G., Klewes, L., Arapovic, D., White, E. K., Koury, M. J., Oltz, E. M., Van Kaer, L., &amp; Ruley, H. E. (2000). Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nature Genetics, 24(2), 175-179.</Citation>
        </Reference>
        <Reference>
          <Citation>Ikenaka, K., Ishigaki, S., Iguchi, Y., Kawai, K., Fujioka, Y., Yokoi, S., Abdelhamid, R. F., Nagano, S., Mochizuki, H., Katsuno, M., &amp; Sobue, G. (2020). Characteristic features of FUS inclusions in spinal motor neurons of sporadic amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 79(4), 370-377.</Citation>
        </Reference>
        <Reference>
          <Citation>Kalliolias, G. D., &amp; Ivashkiv, L. B. (2016). TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nature Reviews Rheumatology, 12(1), 49-62.</Citation>
        </Reference>
        <Reference>
          <Citation>Kamo, H., Haebara, H., Akiguchi, I., Kameyama, M., Kimura, H., &amp; McGeer, P. L. (1987). A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathologica, 74(1), 33-38.</Citation>
        </Reference>
        <Reference>
          <Citation>Kemanetzoglou, E., &amp; Andreadou, E. (2017). CNS demyelination with TNF-alpha blockers. Current Neurology and Neuroscience Reports, 17(4), 36.</Citation>
        </Reference>
        <Reference>
          <Citation>Kia, A., McAvoy, K., Krishnamurthy, K., Trotti, D., &amp; Pasinelli, P. (2018). Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. GLIA, 66(5), 1016-1033.</Citation>
        </Reference>
        <Reference>
          <Citation>Kiaei, M., Petri, S., Kipiani, K., Gardian, G., Choi, D. K., Chen, J., Calingasan, N. Y., Schafer, P., Muller, G. W., Stewart, C., Hensley, K., &amp; Beal, M. F. (2006). Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience, 26(9), 2467-2473.</Citation>
        </Reference>
        <Reference>
          <Citation>Kimura, T., &amp; Budka, H. (1984). Glial bundles in spinal nerve roots. An immunocytochemical study stressing their nonspecificity in various spinal cord and peripheral nerve diseases. Acta Neuropathologica, 65(1), 46-52.</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayashi, Z., Tsuchiya, K., Arai, T., Aoki, M., Hasegawa, M., Ishizu, H., Akiyama, H., &amp; Mizusawa, H. (2010). Occurrence of basophilic inclusions and FUS-immunoreactive neuronal and glial inclusions in a case of familial amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 293(1-2), 6-11.</Citation>
        </Reference>
        <Reference>
          <Citation>Kushner, P. D., Stephenson, D. T., &amp; Wright, S. (1991). Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. Journal of Neuropathology and Experimental Neurology, 50(3), 263-277.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwiatkowski, T. J., Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., Valdmanis, P., Rouleau, G. A., Hosler, B. A., Cortelli, P., de Jong, P. J., Yoshinaga, Y., Haines, J. L., Pericak-Vance, M. A., Yan, J., &amp; Brown, R. H., Jr. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323(5918), 1205-1208.</Citation>
        </Reference>
        <Reference>
          <Citation>Li, K., Hala, T. J., Seetharam, S., Poulsen, D. J., Wright, M. C., &amp; Lepore, A. C. (2015). GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease. Neurobiology of Disease, 78, 12-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Li, K., Nicaise, C., Sannie, D., Hala, T. J., Javed, E., Parker, J. L., Putatunda, R., Regan, K. A., Suain, V., Brion, J. P., Rhoderick, F., Wright, M. C., Poulsen, D. J., &amp; Lepore, A. C. (2014). Overexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury. The Journal of Neuroscience, 34(22), 7622-7638.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu, C. H., Allen, K., Oei, F., Leoni, E., Kuhle, J., Tree, T., Fratta, P., Sharma, N., Sidle, K., Howard, R., Orrell, R., Fish, M., Greensmith, L., Pearce, N., Gallo, V., &amp; Malaspina, A. (2016). Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurology Neuroimmunology &amp; Neuroinflammation, 3(4), e244.</Citation>
        </Reference>
        <Reference>
          <Citation>Machamer, J. B., Collins, S. E., &amp; Lloyd, T. E. (2014). The ALS gene FUS regulates synaptic transmission at the drosophila neuromuscular junction. Human Molecular Genetics, 23(14), 3810-3822.</Citation>
        </Reference>
        <Reference>
          <Citation>McCauley, M. E., &amp; Baloh, R. H. (2019). Inflammation in ALS/FTD pathogenesis. Acta Neuropathologica, 137(5), 715-730.</Citation>
        </Reference>
        <Reference>
          <Citation>McCoy, M. K., &amp; Tansey, M. G. (2008). TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. Journal of Neuroinflammation, 5, 45.</Citation>
        </Reference>
        <Reference>
          <Citation>Meyer, K., Ferraiuolo, L., Miranda, C. J., Likhite, S., McElroy, S., Renusch, S., Ditsworth, D., Lagier-Tourenne, C., Smith, R. A., Ravits, J., Burghes, A. H., Shaw, P. J., Cleveland, D. W., Kolb, S. J., &amp; Kaspar, B. K. (2014). Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proceedings of the National Academy of Sciences of the United States of America, 111(2), 829-832.</Citation>
        </Reference>
        <Reference>
          <Citation>Migheli, A., Piva, R., Atzori, C., Troost, D., &amp; Schiffer, D. (1997). C-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 56(12), 1314-1322.</Citation>
        </Reference>
        <Reference>
          <Citation>Mizielinska, S., Lashley, T., Norona, F. E., Clayton, E. L., Ridler, C. E., Fratta, P., &amp; Isaacs, A. M. (2013). C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathologica, 126(6), 845-857.</Citation>
        </Reference>
        <Reference>
          <Citation>Mulder, D. W. (1982). Clinical limits of amyotrophic lateral sclerosis. Advances in Neurology, 36, 15-22.</Citation>
        </Reference>
        <Reference>
          <Citation>Murayama, S., Inoue, K., Kawakami, H., Bouldin, T. W., &amp; Suzuki, K. (1991). A unique pattern of astrocytosis in the primary motor area in amyotrophic lateral sclerosis. Acta Neuropathologica, 82(6), 456-461.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., &amp; Przedborski, S. (2007). Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature Neuroscience, 10(5), 615-622.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagy, D., Kato, T., &amp; Kushner, P. D. (1994). Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. Journal of Neuroscience Research, 38(3), 336-347.</Citation>
        </Reference>
        <Reference>
          <Citation>Novrup, H. G., Bracchi-Ricard, V., Ellman, D. G., Ricard, J., Jain, A., Runko, E., Lyck, L., Yli-Karjanmaa, M., Szymkowski, D. E., Pearse, D. D., Lambertsen, K. L., &amp; Bethea, J. R. (2014). Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroinflammation, 11, 159.</Citation>
        </Reference>
        <Reference>
          <Citation>Pasparakis, M., Alexopoulou, L., Episkopou, V., &amp; Kollias, G. (1996). Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. The Journal of Experimental Medicine, 184(4), 1397-1411.</Citation>
        </Reference>
        <Reference>
          <Citation>Pekalski, J., Zuk, P. J., Kochanczyk, M., Junkin, M., Kellogg, R., Tay, S., &amp; Lipniacki, T. (2013). Spontaneous NF-kappaB activation by autocrine TNFalpha signaling: A computational analysis. PLoS One, 8(11), e78887.</Citation>
        </Reference>
        <Reference>
          <Citation>Phatnani, H. P., Guarnieri, P., Friedman, B. A., Carrasco, M. A., Muratet, M., O'Keeffe, S., Nwakeze, C., Pauli-Behn, F., Newberry, K. M., Meadows, S. K., Tapia, J. C., Myers, R. M., &amp; Maniatis, T. (2013). Intricate interplay between astrocytes and motor neurons in ALS. Proceedings of the National Academy of Sciences of the United States of America, 110(8), 756-765.</Citation>
        </Reference>
        <Reference>
          <Citation>Poloni, M., Facchetti, D., Mai, R., Micheli, A., Agnoletti, L., Francolini, G., Mora, G., Camana, C., Mazzini, L., &amp; Bachetti, T. (2000). Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neuroscience Letters, 287(3), 211-214.</Citation>
        </Reference>
        <Reference>
          <Citation>Popova, L. M., &amp; Sakharova, A. V. (1982). Virus-like inclusions in the cells of the central nervous system in amyotrophic lateral sclerosis. Arkhiv Patologii, 44(10), 28-33.</Citation>
        </Reference>
        <Reference>
          <Citation>Qian, K., Huang, H., Peterson, A., Hu, B., Maragakis, N. J., Ming, G. L., Chen, H., &amp; Zhang, S. C. (2017). Sporadic ALS astrocytes induce neuronal degeneration in vivo. Stem Cell Reports, 8(4), 843-855.</Citation>
        </Reference>
        <Reference>
          <Citation>Qosa, H., Lichter, J., Sarlo, M., Markandaiah, S. S., McAvoy, K., Richard, J. P., Jablonski, M. R., Maragakis, N. J., Pasinelli, P., &amp; Trotti, D. (2016). Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. GLIA, 64(8), 1298-1313.</Citation>
        </Reference>
        <Reference>
          <Citation>Rademakers, R., Stewart, H., Dejesus-Hernandez, M., Krieger, C., Graff-Radford, N., Fabros, M., Briemberg, H., Cashman, N., Eisen, A., &amp; Mackenzie, I. R. (2010). Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle &amp; Nerve, 42(2), 170-176.</Citation>
        </Reference>
        <Reference>
          <Citation>Renton, A. E., Chio, A., &amp; Traynor, B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 17(1), 17-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Rostalski, H., Leskela, S., Huber, N., Katisko, K., Cajanus, A., Solje, E., Marttinen, M., Natunen, T., Remes, A. M., Hiltunen, M., &amp; Haapasalo, A. (2019). Astrocytes and microglia as potential contributors to the pathogenesis of C9orf72 repeat expansion-associated FTLD and ALS. Frontiers in Neuroscience, 13, 486.</Citation>
        </Reference>
        <Reference>
          <Citation>Santello, M., Bezzi, P., &amp; Volterra, A. (2011). TNFalpha controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron, 69(5), 988-1001.</Citation>
        </Reference>
        <Reference>
          <Citation>Scekic-Zahirovic, J., Oussini, H. E., Mersmann, S., Drenner, K., Wagner, M., Sun, Y., Allmeroth, K., Dieterle, S., Sinniger, J., Dirrig-Grosch, S., Rene, F., Dormann, D., Haass, C., Ludolph, A. C., Lagier-Tourenne, C., Storkebaum, E., &amp; Dupuis, L. (2017). Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathologica, 133(6), 887-906.</Citation>
        </Reference>
        <Reference>
          <Citation>Sedger, L. M., &amp; McDermott, M. F. (2014). TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine &amp; Growth Factor Reviews, 25(4), 453-472.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma, A., Lyashchenko, A. K., Lu, L., Nasrabady, S. E., Elmaleh, M., Mendelsohn, M., Nemes, A., Tapia, J. C., Mentis, G. Z., &amp; Shneider, N. A. (2016). ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nature Communications, 7, 10465.</Citation>
        </Reference>
        <Reference>
          <Citation>Stellwagen, D., Beattie, E. C., Seo, J. Y., &amp; Malenka, R. C. (2005). Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. The Journal of Neuroscience, 25(12), 3219-3228.</Citation>
        </Reference>
        <Reference>
          <Citation>Stellwagen, D., &amp; Malenka, R. C. (2006). Synaptic scaling mediated by glial TNF-alpha. Nature, 440(7087), 1054-1059.</Citation>
        </Reference>
        <Reference>
          <Citation>Stommel, E. W., Cohen, J. A., Fadul, C. E., Cogbill, C. H., Graber, D. J., Kingman, L., Mackenzie, T., Channon Smith, J. Y., &amp; Harris, B. T. (2009). Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial. Amyotrophic Lateral Sclerosis, 10(5-6), 393-404.</Citation>
        </Reference>
        <Reference>
          <Citation>Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., McLaughlin, P., Snowden, J., Mioshi, E., Roberts-South, A., Benatar, M., HortobaGyi, T., Rosenfeld, J., Silani, V., Ince, P. G., &amp; Turner, M. R. (2017). Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18(3-4), 153-174.</Citation>
        </Reference>
        <Reference>
          <Citation>Suzuki, N., Kato, S., Kato, M., Warita, H., Mizuno, H., Kato, M., Shimakura, N., Akiyama, H., Kobayashi, Z., Konno, H., &amp; Aoki, M. (2012). FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation. Journal of Neuropathology and Experimental Neurology, 71(9), 779-788.</Citation>
        </Reference>
        <Reference>
          <Citation>Swarup, V., Phaneuf, D., Dupre, N., Petri, S., Strong, M., Kriz, J., &amp; Julien, J. P. (2011). Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. The Journal of Experimental Medicine, 208(12), 2429-2447.</Citation>
        </Reference>
        <Reference>
          <Citation>Tateishi, T., Yamasaki, R., Tanaka, M., Matsushita, T., Kikuchi, H., Isobe, N., Ohyagi, Y., &amp; Kira, J. (2010). CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. Journal of Neuroimmunology, 222(1-2), 76-81.</Citation>
        </Reference>
        <Reference>
          <Citation>Tolosa, L., Caraballo-Miralles, V., Olmos, G., &amp; Llado, J. (2011). TNF-alpha potentiates glutamate-induced spinal cord motoneuron death via NF-kappaB. Molecular and Cellular Neurosciences, 46(1), 176-186.</Citation>
        </Reference>
        <Reference>
          <Citation>Tong, J., Huang, C., Bi, F., Wu, Q., Huang, B., Liu, X., Li, F., Zhou, H., &amp; Xia, X. G. (2013). Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. The EMBO Journal, 32(13), 1917-1926.</Citation>
        </Reference>
        <Reference>
          <Citation>Tortarolo, M., Lo Coco, D., Veglianese, P., Vallarola, A., Giordana, M. T., Marcon, G., Beghi, E., Poloni, M., Strong, M. J., Iyer, A. M., Aronica, E., &amp; Bendotti, C. (2017). Amyotrophic lateral sclerosis, a multisystem pathology: Insights into the role of TNFalpha. Mediators of Inflammation, 2017, 2985051.</Citation>
        </Reference>
        <Reference>
          <Citation>Tripathi, P., Rodriguez-Muela, N., Klim, J. R., de Boer, A. S., Agrawal, S., Sandoe, J., Lopes, C. S., Ogliari, K. S., Williams, L. A., Shear, M., Rubin, L. L., Eggan, K., &amp; Zhou, Q. (2017). Reactive astrocytes promote ALS-like degeneration and intracellular protein aggregation in human motor neurons by disrupting autophagy through TGF-beta1. Stem Cell Reports, 9(2), 667-680.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyzack, G. E., Hall, C. E., Sibley, C. R., Cymes, T., Forostyak, S., Carlino, G., Meyer, I. F., Schiavo, G., Zhang, S. C., Gibbons, G. M., Newcombe, J., Patani, R., &amp; Lakatos, A. (2017). A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nature Communications, 8(1), 1164.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyzack, G. E., Luisier, R., Taha, D. M., Neeves, J., Modic, M., Mitchell, J. S., Meyer, I., Greensmith, L., Newcombe, J., Ule, J., Luscombe, N. M., &amp; Patani, R. (2019). Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain, 142(9), 2572-2580.</Citation>
        </Reference>
        <Reference>
          <Citation>Valori, C. F., Brambilla, L., Martorana, F., &amp; Rossi, D. (2014). The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cellular and Molecular Life Sciences, 71(2), 287-297.</Citation>
        </Reference>
        <Reference>
          <Citation>Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K. L., Tripathi, V., Al-Saraj, S., Al-Chalabi, A., Leigh, P. N., Blair, I. P., Nicholson, G., de Belleroche, J., &amp; Shaw, C. E. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323(5918), 1208-1211.</Citation>
        </Reference>
        <Reference>
          <Citation>Vance, C., Scotter, E. L., Nishimura, A. L., Troakes, C., Mitchell, J. C., Kathe, C., Urwin, H., Manser, C., Miller, C. C., Hortobagyi, T., Dragunow, M., Rogelj, B., &amp; Shaw, C. E. (2013). ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Human Molecular Genetics, 22(13), 2676-2688.</Citation>
        </Reference>
        <Reference>
          <Citation>Via, C. S., Shustov, A., Rus, V., Lang, T., Nguyen, P., &amp; Finkelman, F. D. (2001). In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. Journal of Immunology, 167(12), 6821-6826.</Citation>
        </Reference>
        <Reference>
          <Citation>Vucic, S., Rothstein, J. D., &amp; Kiernan, M. C. (2014). Advances in treating amyotrophic lateral sclerosis: Insights from pathophysiological studies. Trends in Neurosciences, 37(8), 433-442.</Citation>
        </Reference>
        <Reference>
          <Citation>Wachter, N., Storch, A., &amp; Hermann, A. (2015). Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16(7-8), 431-441.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, R., Yang, B., &amp; Zhang, D. (2011). Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. GLIA, 59(6), 946-958.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou, Z. Y., Liu, M. S., Li, X. G., &amp; Cui, L. Y. (2016). Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(3-4), 249-252.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou, Z. Y., Zhou, Z. R., Che, C. H., Liu, C. Y., He, R. L., &amp; Huang, H. P. (2017). Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery, and Psychiatry, 88(7), 540-549.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
